Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol

Figures & data

Figure 1 Schematic representation of synergic mechanisms of antimuscarinic agents, beta-2 agonists, and inhaled corticosteroids.

Abbreviations: LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist.

Table 1 Studies comparing ELLIPTA with other devices

Study	Year	Number of COPD patients	Primary endpoint	Results
Svedsater et al^Citation61	2013	42	Comparison among ELLIPTA and other devices about their satisfaction with various attributes of the inhalers	The ELLIPTA was associated with high patient satisfaction and was preferred to other inhalers when participants with asthma and COPD were interviewed
Komase et al^Citation65	2014	150	Preference for ease of use between ELLIPTA and the Breezhaler device	The ELLIPTA was preferred for ease of use and number of steps
van der Palen et al^Citation62	2016	567	Errors in the use of the ELLIPTA compared to other devices	Fewer errors in patients using ELLIPTA in naive patients
Yun Kirby et al^Citation63	2016	287	Inhale preference based on size of the numbers on the dose counter	More patients preferred five specific inhaler attributes of the ELLIPTA when compared with Diskus
Collison et al^Citation64	2018	214	Preference between ELLIPTA and Handihaler based on the number of steps needed to use the inhaler	Preference for ELLIPTA

SvedsaterHDalePGarrillKWalkerRWoepseMWQualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123

 PubMed Web of Science ®Google Scholar

KomaseYAsakoAKobayashiASharmaREase-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or olderInt J Chron Obstruct Pulmon Dis201491365137525525354

 PubMed Web of Science ®Google Scholar

van der PalenJThomasMChrystynHA randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devicesNPJ Prim Care Respir Med2016261607927883002

 PubMed Web of Science ®Google Scholar

Yun KirbySZhuCQKerwinEMStanfordRHGeorgesGA preference study of two placebo dry powder inhalers in adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPICOPD201613216717526516724

 PubMedGoogle Scholar

CollisonKAPatelPPreeceAFStanfordRHSharmaRKFeldmanGA randomized clinical trial comparing the ELLIPTA and HandiHaler dry powder inhalers in patients with COPD: inhaler-specific attributes and overall patient preferenceCOPD2018151465029227727

 PubMedGoogle Scholar